je.st
news
Systematic Review of 58 Publications of Real-World Use of GARDASIL Presented at EUROGIN Congress
2016-06-16 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that in a systematic review conducted of the global impact and effectiveness of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial reductions were observed in HPV 6/11/16/18-related infection, genital warts, Pap abnormalities and cervical pre-cancers. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
publications
presented
congress
Category:Biotechnology and Pharmaceuticals